VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 107 filers reported holding VAXCYTE INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,716,689 | -9.9% | 2,093,305 | -11.7% | 0.61% | +1.3% |
| Q2 2023 | $118,418,627 | +274.0% | 2,371,218 | +180.7% | 0.60% | +258.0% |
| Q1 2023 | $31,662,279 | -24.7% | 844,778 | -3.7% | 0.17% | -25.9% |
| Q4 2022 | $42,066,199 | +17877.0% | 877,293 | +8965.8% | 0.23% | +22700.0% |
| Q1 2022 | $234,000 | – | 9,677 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |